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A recombinant antigen (p22-NS3), possessing putative HCV nucleocapsid protein (~22) and non-structural protein 3 (NS3) epitopes, was heavily 
expressed m E. co11 and purified. The p22-NS3 purified recombmant antigen strongly reacts with sera containing human antibodies directed against 
p22 and NS3 providing a starting point for the design of an HCV single all-encompassmg antigen for a blood screening assay. 
Hepatitis C virus: Antigen; Fusion protein; Purification. Antibody 
1. INTRODUCTION 
Non-A non-B hepatitis (NANBH) is a transmittable 
disease for which the etiological agents are distinct from 
hepatotropic viruses such as hepatitis A, B and delta [l]. 
The etiological agent of NANBH was identified by 
Choo and coworkers in 1989 [2-53 and denominated 
hepatitis C virus (HCV). The viral genome is a positive 
stranded RNA of about 9.4 kb [2] encoding a putative 
polyprotein of 3010-3011 amino acids [&lo]. The HCV 
genome codes for three structural proteins (putative nu- 
cleocapsid protein, putative matrix, envelope) and six 
non-structural proteins (NSl. NS2, NS3. NS4a. NS4b 
and NS5) [7,11]. 
For diagnosis of HCV infection, structural and non- 
structural regions of HCV-encoded polyprotein have 
been expressed in various heterologous systems [ 12- 141. 
The recombinant proteins were used either individually 
or combined to capture anti-HCV antibodies [ 12,15,16]. 
However, immunological studies have shown that the 
most important epitopes lie within the putative nucleo- 
capsid protein (~22) [13,17] and in the non-structural 
protein 3 (NS3) and 4 (NS4) [18]. In this paper we 
evaluate the usefulness of a chimeric protein containing 
epitopes of both p22 and NS3 for the design of a HCV 
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single all-encompassing antigen for a blood screening 
assay. We have expressed in E. coli a chimeric protein 
made of amino acids l-105 of ~22 and amino acids 
1186-1364 of NS3 and we have tested its immunoreac- 
tivity against anti-HCV positive sera. The purified 
chimeric protein (p22-NS3) was shown to bind to sera 
from HCV infected patients showing anti-p22 and anti- 
NS3 immunoreactivities. 
2. MATERIALS AND METHODS 
Culture media, salts, and solvents were purchased from Sigma 
(USA); gel-filtration resins were purchased from Pharmacia (Sweden); 
ohgonucleotides were synthesized using a Beckman Synthesizer 
(USA): panels of certified HCV positive and negative sera were pur- 
chased from BBI (USA): plasmtd pVLl393 was purchased from Strat- 
agene (USA), plasmid pGEX-3X was purchased from Promega 
(USA); Anti-HCV antibody detection kits were supplied by SORIN 
Biomedica (Italy). 
1.2. Cloning ofp2,7-NS3 vt E colt 
Partial HCV ~32 gene (nucleotide position -21 to 491) and partial 
NS3 gene (nucleotide position 3549 to 4092) were obtained from 
lambda clones of HCV genome fragments (F. Bonelli. unpubhshed 
results) usmg polymerase chain reaction amplification (PCR) [20]. The 
cloning strategy IS described in Fig. 1. 
Bacterial culture (RR]) [21] transformed with pEV22-NS3 was 
grown at 30°C m LB medium [22] (500 ml) supplemented with 50 mg/l 
ampicillm When the cells density reached an A,,, = 0 5 the culture was 
transferred to 42°C. After 4 h induction, cells were collected by centnf- 
ugdtion. 
2.4. C’ellulur lysrs 
E. co11 cells (7.6 g). strain RR], transformed with pEV22-NS3, were 
suspended m 19 ml buffer A (50 mM Tris-HCl pH 8.0, 100 mM NaCl. 
1 mM EDTA). The suspension was sonicated (3 x 100 W burst. 5°C) 
and then clarified by centrifugation (20 mm. 10,000 x g. 10°C). Cellu- 
Puhlisld by Elsevier Screncr Publtshers B k 253 
Volume 324. number 3 FEBS LETTERS June 1993 
lar debris were subsequently extracted with 12 ml buffer B (50 mM 
Tris-HC1 pH 8.0, 100 mM NaCI, 1 mM EDTA, 2% Triton X-100) (60 
min. 4°C). The solution was clarified by centrifugatton as described 
above. The pellet was dissolved m buffer C (7 M CH,ClN,, 50 mM 
sodmm acetate pH 5.0, 10 mM ,&mercaptoethanol). Incubated for 30 
min at 60°C. 5 min at 95°C and then the solution was clarified by 
centrifugation. An aliquot of the clarified solution (0.1 ml) was dial- 
ized against buffer D (8 M urea, 50 mM HEPES pH 7.0, 10 mM 
/&mercaptoethanol). 1 ~1 of the dialized solution was loaded on a 
12.5% acrylamide SDS PAGE (Fig. 2, lane 2). 
2.5. Gel-filtration chronzatographJ 
The clear supernatant was loaded onto a Sephacryl S300 HR gel- 
filtration column (2.5 cm x 100 cm) equilibrated in buffer C (flow 
rate = 2 ml/min, detector 280 nm). The eluted material was collected 
m 5 ml fractions The peak fractions, containing the higher level of 
p22-NS3 immunological reactivity (hatched peak. Fig. 3A). were 
pooled. The immunoreactive peak was dialized against buffer D 1 p1 
of the diahzed pool was loaded on a 12 5% acrylamtde SDS-PAGE 
(Fig. 2. lane 3). 
2.6. Ion exchange chrornatograplzJ 
The gel filtration pool. after dialysis, was loaded onto a CM-Sepha- 
rose FF column (15 mm x 40 mm) equilibrated in buffer D (flow 
rate = 2 ml/min, detector 280 nm). The unbound material was washed 
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proteins are eluted with 0.5 M NaCl in buffer D (flow rate 2 ml/min). 
The peak fractions, containing the higher level of p22-NS3 immunol- 
ogical reactivity (hatched peak, Fig. 3B). were pooled. I pi of the 
diahzed pool was loaded on a 12.5% acrylamidr SDS PAGE (Fig. 2, 
lane 4). 
2.7. p_7_1-NS3 refoldmg 
The p22-NS3 recombinant polypepttde was refolded m vitro as 
described by J.L. Cleland [23]. Purified p22-NS3 (30 ,uM, 3 ml). in 
presence of PEG 3350 with a PEG to p22-NS3 molar ratio of 10 to 
1, was dialyzed agamst 500 ml 8 M urea in buffer E (100 mM HEPES 
pH 6.0. 0.5 M NaCl) using a 1 kDa cut-off dialysis tube. under 
nitrogen atmosphere at 4°C. The urea concentration in buffer E was 
reduced to zero by a step of 2 M every 2 hours. Then the p22-NS3 was 
extensively dialyzed against buffer E. At the end of the refolding 
procedure the recombinant polypepttde p22-NS3 was soluble in buffer 
E (100 mM HEPES pH 6 0. 0.5 M NaCI). 
Western blot analysis was done on purified p22-NS3 recombinant 
protein. wtth sera from HCV Infected patients showing anti-NS3 and 
anti-p22 tmmunoreactivmes (data not shown), usmg a modified Tow- 
bin’s protocol [24] p22-NS3 immunoreactivity detection m column 
eluates (data not shown) was performed using Western Blot analysis. 
with anti-p22 IgG purified from a pool of HCV infected human sera. 
ELlSA assays (Fig. 4) were performed as previously described [25] 
Fig. 1 The p22 and NS3 partial gene fragments were cloned m pVL1393 (pVL22, pVLNS3) (R. Calogero. personal commumcation). The gene 
fragment BamHIIAlul from pVL22, encoding amino acids 1 to 105 of p22 gene, was ligated with fragment BarriHI (filled in)lEcuRI from pVLNS3. 
encoding amino acids 1186-1364 of NS3 gene. The chimeric gene was cloned m pGEX-3X cut Bu~iHIIE~~oRI (pGE.X22-NS3). excised by EcoRI 
digestion and cloned m pEV1 [20] cut EcoRI (pEV22-NS3). 
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3. RESULTS AND DISCUSSION 
We have cloned (Fig. 1) and expressed in E. coli a 
recombinant chimeric p22-NS3 antigen. Nucleotide se- 
quence analysis (data not shown) of the partially cloned 
p22 and NS3 genes has shown homology higher than 
97%. at the amino acid level, with published HCV p22 
and NS3 [6]. 
The purified recombinant p22-NS3 is a fusion protein 
consisting of 3 amino acids (M-N-E) of pEV1 linker 
[20], 9 amino acids (F-R-S-R-R-P-C-I-M) of pVL1393 
polylinker, HCV nucleocapsid protein sequence trun- 
cated at amino acid 105 and the central region of NS3 
protein from amino acid 1186 to 1364. Recombinant 
antigen has a molecular weight of 33 kD (Fig. 2, lane 
4). The sequencing of the first 20 amino acids at the 
NH2-terminus confirmed the sequence predicted from 
the DNA sequencing. The antigen accumulates inside 
the E. coli cells in inclusion bodies and represents about 
2% of the total cell proteins (data not shown). We have 
purified the antigen using a two-steps procedure involv- 
ing gel-filtration and cationic exchange chromatogra- 
phy (Fig. 3A,B). The immunological behavior of the 
recombinant p22-NS3 after gel-filtration was quite 
poor. We have observed false positive reactivities using 
the gel-filtration purified p22-NS3 (data not shown). 
However, following cationic exchange chromatography 
the recombinant antigen has shown a specific binding 
to sera having anti-p22 and anti-NS3 immunoreactivi- 
ties (Fig. 4). Moreover the protein content of the un- 
bound material, eluted from the ionic exchange column, 
was less than l/100 of the purified recombinant antigen. 
At the end of the purification procedure the protein was 
over 95% pure as seen by Coomassie staining (Fig. 2, 
lane 4) and the final yields were of the order 3 mg per 
liter culture. Recombinant antigen after purification 
1 3 ,3 1 
- 49.5 kD 
W - 32.5 kD 
Fig. 2. In the SDS PAGE analysis recombinant p22-NS3 is shown by 
an arrow. Lane 1, Bio-Rad prestained molecular weight markers: lane 
2, E. coli debris dissoved in buffer C; Lane 3, peak fraction pool of 
S300 HR gel-filtration, associated with p22-NS3 immunoreactivity; 
lane 4, peak fraction pool of iomc exchange chromatography, associ- 
ated with p22-NS3 immune-reactivity. 
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Fig. 3. (A) Elution profile of gel-filtration chromatography (see sec- 
tion 2). (B) Elution profile of ionic exchange chromatography (see 
section 2). 
was soluble only in strong denaturants such as urea and 
guanidinium chloride. We have used the refolding pro- 
cedure proposed by J.L. Cleland [23] to obtain a recom- 
binant p22-NS3 soluble in non-denaturant solutions. 
The immunoreactivity of p22-NS3 was compared, in 
indirect ELISA assays, with respect to recombinant p22 
(R. Calogero personal communication). The chimeric 
p22-NS3 protein has shown to react not only with sera 
having anti-p22 immunoreactivity, but also with patient 
sera containing human antibodies directed against NS3 
(Fig. 4, closed bars: sera 8, 10 and, as border line value, 
serum 20). On the other hand recombinant p22 can 
interact only with sera having anti-p22 immunoreactiv- 
ity (Fig. 4, open bars). 
The level of purity and the yield of protein, which we 
achieved, will allow the easy coupling of p22-NS3 with 
enzymes or fluorescent compounds for development of 
antigen labeled sandwich immunoassays [26]. 
It was shown that anti-p22, anti-NS3 and anti-NS4 
immunoreactivities are present in different combina- 
tions in the early stage of HCV infection [18]. However, 
an HCV single all-encompassing antigen for blood 
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Fig. 4. Im~lunoreactivIty of recombinant p22-NS3 as compare to recombinant ~22 antigen was evaluated analyzing then bindrng to antt-HCV 
antibodies. using a certified antt-HCV positrve and negattce sera panel (BBI, USA). Closed bars show the immunoreactivrttes identified with 
chimeric p22-NS3. Open bars show the Immunoreactl~itles ldentl~ed with reconlbi!?ant p 22 On the top of the figure the values for ~22 (C23-cf. 
NS3 (C33-c) and NS4 (C-100) tmmunoreactivttirs are shown These data were obtained by manufacturer usmg a second generation RlBA assay 
for detection of antr-HCV antibodres (Ortho Diagnostics, USA). Values 4 to I indicate clear positive reactititres. +I- and -. respecttveiy, mdcate 
reacttvtties near cut off value and absence of reactrvity. 
screening was not yet developed. The p23-NS3 recombi- 
nant chimeric antigen provides a starting point for the 
assembly of a multi-~CV-epitopes poly~ptide. 
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